Fidaxomicin + Treatment for CDI other than fidaxomicin Type
Pre-clinicalCompleted 0 watching 0 views this week💤 Quiet
23
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Clostridium Difficile Infection
Conditions
Clostridium Difficile Infection
Trial Timeline
Sep 3, 2014 → Aug 17, 2017
NCT ID
NCT02214771About Fidaxomicin + Treatment for CDI other than fidaxomicin Type
Fidaxomicin + Treatment for CDI other than fidaxomicin Type is a pre-clinical stage product being developed by Astellas Pharma for Clostridium Difficile Infection. The current trial status is completed. This product is registered under clinical trial identifier NCT02214771. Target conditions include Clostridium Difficile Infection.
Hype Score Breakdown
Clinical
5
Activity
2
Company
10
Novelty
2
Community
1
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02214771 | Pre-clinical | Completed |
Competing Products
20 competing products in Clostridium Difficile Infection